The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
The stock recently traded at 1 times the next 12-month earnings vs. a P/E of 1 three months ago
2026 outlook raised
Bausch Health raises full-year 2026 revenue guidance to $10.79-$11.04 bln
Company expects 2026 adjusted EBITDA of $4.05-$4.18 bln, up 8%-11% vs prior yr
Company says uncertainty around tariffs may affect results in 2026
BHC•
